Venlafaxineinteractions

Alcohol: Increases the release rate of Venlafaxine Extended-Release Tablets. Avoid concomitant use.

7.1 Drugs Having

Clinically Important Interactions with Venlafaxine Extended-Release Tablets Table 13: Clinically Significant Drug Interactions with Venlafaxine Extended-Release Tablets Monoamine Oxidase Inhibitors (MAOI) Clinical Impact Concomitant use of SNRIs, including Venlafaxine Extended-Release Tablets, with MAOIs increases the risk of serotonin syndrome. Intervention Concomitant use of Venlafaxine Extended-Release Tablets is contraindicated in patients taking MAOIs, including MAOIs such as linezolid or intravenous methylene blue. Other Serotonergic Drugs Clinical Impact Concomitant use of Venlafaxine Extended-Release Tablets with other serotonergic drugs (including other SNRIs, SSRIs, triptans, tricyclic antidepressants, opioids, lithium, buspirone, amphetamines, tryptophan, and St. John's Wort) increases the risk of serotonin syndrome. Intervention Monitor for symptoms of serotonin syndrome when Venlafaxine Extended-Release Tablets is used concomitantly with other drugs that may affect the serotonergic neurotransmitter systems. If serotonin syndrome occurs, consider discontinuation of Venlafaxine Extended-Release Tablets and/or concomitant serotonergic drugs. Alcohol Clinical Impact Based on an in vitro study, alcohol increases the release rate of Venlafaxine Extended-Release Tablets. Intervention Avoid concomitant use of alcohol during treatment with Venlafaxine Extended-Release Tablets. Drugs that Interfere with Hemostasis Clinical Impact Concomitant use of Venlafaxine Extended-Release Tablets with an antiplatelet or anticoagulant drug may potentiate the risk of bleeding. This may be due to the effect of venlafaxine on the release of serotonin by platelets. Intervention Closely monitor patients receiving an antiplatelet or anticoagulant drug for bleeding when Venlafaxine Extended-Release Tablets is initiated or discontinued. CYP3A Inhibitors Clinical Impact Concomitant use of Venlafaxine Extended-Release Tablets with a CYP3A inhibitor increases the C max and AUC of venlafaxine and O-desmethylvenlafaxine (ODV), which may increase the risk of toxicity of venlafaxine. Intervention Consider reducing the dose of Venlafaxine Extended-Release Tablets. CYP2D6 Substrates Clinical Impact Concomitant use of Venlafaxine Extended-Release Tablets with a CYP2D6 substrate increases C max and AUC of the CYP2D6 substrate, which may increase the risk of toxicity of the CYP2D6 substrate. Intervention Consider reduction in dose of concomitant CYP2D6 substrates.

7.2 Other Drug

Interactions with Venlafaxine Extended-Release Tablets Weight Loss Agents The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Coadministration of Venlafaxine Extended-Release Tablets and weight loss agents is not recommended. Venlafaxine Extended-Release Tablets are not indicated for weight loss alone or in combination with other products. Laboratory Test Interference False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.